Stéphane Bancel, Moderna CEO (Fabrice Coffrini/AFP via Getty Images)

Covid-19 roundup: De­sert­ed by Roche and plagued by set­backs, Atea march­es on; Eu­rope lines up or­der for Mod­er­na's Omi­cron boost­er

De­spite ini­tial flops, Jean-Pierre Som­ma­dos­si be­lieves his an­tivi­ral biotech still has a role to play in what he sees as a long fight against Covid-19.

“COVID-19 con­tin­ues to be a glob­al emer­gency with wan­ing ef­fi­ca­cy from vac­cines, ther­a­peu­tics and pri­or in­fec­tions dri­ving an un­met med­ical need. New an­tivi­rals with im­proved pro­files are ur­gent­ly need­ed,” Som­ma­dos­si, the CEO of Atea Phar­ma­ceu­ti­cals, said in a quar­ter­ly up­date.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.